Evidence map›Paper›PMID 36052016›Full record

ArticleCancer research communications2022

Interrogation of T Cell-Enriched Tumors Reveals Prognostic and Immunotherapeutic Implications of Polyamine Metabolism.

R Alex Harbison, Rajeev Pandey, Michael Considine, Robert D Leone, Tracy Murray-Stewart, Rossin Erbe, Raj Mandal, Mark Burns, Robert A Casero, Tanguy Seiwert and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cancer research communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

R Alex HarbisonDepartment of Otolaryngology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Rajeev PandeyDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Michael ConsidineDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Robert D LeoneDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Tracy Murray-StewartDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Rossin ErbeDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Raj MandalDepartment of Otolaryngology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Mark BurnsAminex Therapeutics, Kirkland, WA, USA.
Robert A CaseroDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Tanguy SeiwertDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Carole FakhryDepartment of Otolaryngology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Drew PardollDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Elana FertigDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jonathan D PowellThe Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Bloomberg (United States) · USJohns Hopkins University · USAminex Therapeutics (United States) · US

Funding

TR&D Project 3P41EB028239 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI JOEL CHAIM SUNSHINE · 2019 to 2026
$11.5M
Institutional Career Development CoreKL2TR003099 · NCATS · JOHNS HOPKINS UNIVERSITY · PI GEBO, KELLY A · 2019 to 2023
$7.9M
Identification of novel spermine oxidase (SMOX) inhibitors as probes for an emerging chemoprevention targetR01CA204345 · NCI · JOHNS HOPKINS UNIVERSITY · PI CASERO, ROBERT A., WOSTER, PATRICK M · 2016 to 2020
$3.4M
Self-immolative prodrug/miRNA nanoparticle combinations for cancer treatmentR01CA235863 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI CASERO, ROBERT A., OUPICKY, DAVID · 2019 to 2023
$2.3M
Targeting Tumor Metabolism as a Means of Enhancing ImmunotherapyR01CA226765 · NCI · JOHNS HOPKINS UNIVERSITY · PI LEONE, ROBERT DAVID · 2019 to 2023
$1.9M
NCATS NIH HHS KL2 TR003099NCI NIH HHS R01 CA204345NCI NIH HHS R01 CA226765NCI NIH HHS R01 CA235863NIBIB NIH HHS P41 EB028239
6 · The paper itself

Abstract

Metabolic features of the tumor microenvironment (TME) antagonize anti-tumor immunity. We hypothesized that T cell infiltrated tumors with a known antigen should exhibit superior clinical outcomes, though some fare worse given unfavorable metabolic features leveraging T cell-infiltrated (Thi), human papillomavirus-related (HPV+) head and neck squamous cell carcinomas (HNSC) to test this hypothesis. Expression of 2,520 metabolic genes were analyzed among Thi HPV+ HNSCs stratified by high-risk molecular subtype. RNAseq data from The Cancer Genome Atlas (TCGA; 10 cancer types), single cell RNAseq data, and an immunotherapy-treated melanoma cohort were used to test the association between metabolic gene expression and clinical outcomes and contribution of tumor versus stromal cells to metabolic gene expression. Polyamine (PA) metabolism genes were overexpressed in high-risk, Thi HPV+ HNSCs. Genes involved in PA biosynthesis and transport were associated with T cell infiltration, recurrent or persistent cancer, overall survival status, primary site, molecular subtype, and

Indexed as

Head and Neck NeoplasmsPapillomavirus InfectionsHumansImmunotherapyPrognosisPutrescineTumor MicroenvironmentPutrescinehead and neck cancerHuman papillomavirusimmunometabolismpolyamines

Identifiers

PMID36052016
PMCPMC9432485
OpenAlexW4283576630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.